{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:06:08Z","timestamp":1769043968567,"version":"3.49.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,28]]},"abstract":"<jats:p>As the 2nd-leading cause of death, cancer poses a serious danger to human life and health. The pathogenesis and progression of various cancer types are exceedingly intricate. Attention has been drawn to cuproptosis, a recently identified cell death mechanism. Dihydrolipoamide S-acetyltransferase (DLAT), functioning as a target during copper-induced cell death, assumes a crucial role. Hence, investigating the impact of the DLAT gene on the occurrence and development of diverse cancers becomes highly imperative. Employing a pan-cancer analysis approach, we conducted a comprehensive examination of DLAT expression and prognosis across 33 cancers. To accomplish this, we accessed datasets from the University of California Santa Cruz xene database, CellMiner database, and Gene Set Enrichment Analysis official website. The gene expression data and survival data of 10991 samples were analyzed. By utilizing Gene Set Enrichment Analysis, we explored potential pathways involving DLAT. Additionally, the relationship between DLAT expression and the tumor microenvironment, immune infiltration, tumor mutational burden, microsatellite instability, co-expression of immune marker genes, and the sensitivity of common chemotherapy drugs in the 33 cancers was also examined using the Spearman correlation test. In the majority of cancers, the DLAT gene has differential expression that is statistically significant, and this variation in expression is associated with varied prognoses for survival. We observed that DLAT was related with an unfavorable prognosis in pancreatic adenocarcinoma, liver hepatocellular carcinoma, head and neck squamous cell carcinoma, and uveal melanoma, whereas it exhibited a favorable survival trend in colon adenocarcinoma, kidney renal clear cell carcinoma, and rectal adenocarcinoma. Notably, in these tumors, immune-related analyses revealed significant correlations between DLAT and immune markers, such as immune infiltration, tumor mutational burden, and microsatellite instability. Considering the prognostic implications of DLAT in tumors and its correlations with immune indicators, it is plausible to regard DLAT as both a prognosis feature for certain malignancies and an evaluative metric for immunotherapy efficacy. The findings suggest that DLAT could be a potential therapeutic target and serve as a biomarker for predicting patient outcomes and guiding treatment strategies in various cancers, with its prognostic and immunological implications likely to be context-dependent across different tumor types.<\/jats:p>","DOI":"10.1097\/md.0000000000045876","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:00:51Z","timestamp":1764597651000},"page":"e45876","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A pan-cancer analysis to predict the prognosis and immunological role of copper death-related gene DLAT"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2642-1713","authenticated-orcid":false,"given":"Chao","family":"Ding","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, Shengli Oilfield Central Hospital, Dongying, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gu","family":"A","sequence":"additional","affiliation":[{"name":"The Third Norman Bethune Clinical Medical College of Jilin University, Changchun, China"},{"name":"First Affiliated Hospital of Baotou Medical College, Baotou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueke","family":"Tian","sequence":"additional","affiliation":[{"name":"The Third Norman Bethune Clinical Medical College of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8169-2464","authenticated-orcid":false,"given":"Caixia","family":"Sun","sequence":"additional","affiliation":[{"name":"The Third Norman Bethune Clinical Medical College of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260121","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide.","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"key":"R2-20260121","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes.","volume":"578","author":"Aaltonen","year":"2020","journal-title":"Nature"},{"key":"R3-20260121","first-page":"7","article-title":"Visualization and analysis in the field of pan-cancer studies and its application in breast cancer treatment.","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Med"},{"key":"R4-20260121","first-page":"968","article-title":"The effect of copper and other metal ions on the antitumor activity of pyruvaldehyde bis(thiosemicarbazone).","volume":"27","author":"Cappuccino","year":"1967","journal-title":"Cancer Res"},{"key":"R5-20260121","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1039\/C9BM01841G","article-title":"N-Oxide polymer-cupric ion nanogels potentiate disulfiram for cancer therapy.","volume":"8","author":"Zhong","year":"2020","journal-title":"Biomater Sci"},{"key":"R6-20260121","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.abf0529","article-title":"Copper induces cell death by targeting lipoylated TCA cycle proteins.","volume":"375","author":"Tsvetkov","year":"2022","journal-title":"Science"},{"key":"R7-20260121","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41392-022-01014-x","article-title":"Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway.","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"R8-20260121","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40364-022-00446-5","article-title":"Pan-cancer patterns of cuproptosis markers reveal biologically and clinically relevant cancer subtypes.","volume":"11","author":"Bu","year":"2023","journal-title":"Biomarker Res"},{"key":"R9-20260121","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12935-025-03656-7","article-title":"DLAT is involved in ovarian cancer progression by modulating lipid metabolism through the JAK2\/STAT5A\/SREBP1 signaling pathway.","volume":"25","author":"Wang","year":"2025","journal-title":"Cancer Cell Int"},{"key":"R10-20260121","doi-asserted-by":"crossref","first-page":"1061382","DOI":"10.3389\/fgene.2022.1061382","article-title":"The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma.","volume":"13","author":"Sun","year":"2022","journal-title":"Front Genet"},{"key":"R11-20260121","doi-asserted-by":"crossref","first-page":"984158","DOI":"10.3389\/fgene.2022.984158","article-title":"Cuproptosis-related genes in the prognosis of colorectal cancer and their correlation with the tumor microenvironment.","volume":"13","author":"Wu","year":"2022","journal-title":"Front Genet"},{"key":"R12-20260121","first-page":"1","article-title":"Cuprotosis-related genes: predicting prognosis and immunotherapy sensitivity in pancreatic cancer patients. Zheng M, ed.","volume":"2022","author":"Xu","year":"2022","journal-title":"J Oncol"},{"key":"R13-20260121","first-page":"4","article-title":"Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer.","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"key":"R14-20260121","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data.","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"R15-20260121","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony.","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat Methods"},{"key":"R16-20260121","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fgene.2022.962028","article-title":"Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer.","volume":"13","author":"Xiao","year":"2022","journal-title":"Front Genet"},{"key":"R17-20260121","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R18-20260121","first-page":"7","article-title":"Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response.","volume":"22","author":"Fei","year":"2021","journal-title":"Brief Bioinform"},{"key":"R19-20260121","first-page":"6","article-title":"The Challenges of tumor mutational burden as an immunotherapy biomarker.","volume":"39","author":"Denis","year":"2021","journal-title":"Cancer cell"},{"key":"R20-20260121","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements.","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"R21-20260121","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy.","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R22-20260121","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fphar.2022.1074123","article-title":"Prognostic and immune correlation evaluation of a novel cuproptosis-related genes signature in hepatocellular carcinoma.","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"R23-20260121","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett"},{"key":"R24-20260121","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression.","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"R25-20260121","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis.","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"R26-20260121","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/path.1027","article-title":"The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.","volume":"196","author":"Bingle","year":"2002","journal-title":"J Pathol"},{"key":"R27-20260121","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma.","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"key":"R28-20260121","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/febs.14343","article-title":"The roles of CSFs on the functional polarization of tumor-associated macrophages.","volume":"285","author":"Jeannin","year":"2018","journal-title":"FEBS J"},{"key":"R29-20260121","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccr.2013.06.017","article-title":"Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.","volume":"24","author":"Putoczki","year":"2013","journal-title":"Cancer Cell"},{"key":"R30-20260121","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/eji.201847659","article-title":"Targeting Treg cells in cancer immunotherapy.","volume":"49","author":"Tanaka","year":"2019","journal-title":"Eur J Immunol"},{"key":"R31-20260121","doi-asserted-by":"crossref","first-page":"103374","DOI":"10.1016\/j.critrevonc.2021.103374","article-title":"TMB or not TMB as a biomarker: that is the question.","volume":"163","author":"Addeo","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"R32-20260121","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.3390\/cancers14215433","article-title":"Interplay between tumor mutational burden and mutational profile and its effect on overall survival: a pilot study of metastatic patients treated with immune checkpoint inhibitors.","volume":"14","author":"Xavier","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R33-20260121","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.7150\/jca.102256","article-title":"Pan-cancer analysis of DLAT reveals it as a prognostic biomarker involved in immune infiltration of liver hepatocellular carcinoma.","volume":"16","author":"Xu","year":"2025","journal-title":"J Cancer"},{"key":"R34-20260121","doi-asserted-by":"crossref","first-page":"103597","DOI":"10.1016\/j.critrevonc.2022.103597","article-title":"Can the tumor-agnostic evaluation of MSI\/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?","volume":"170","author":"Fanale","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"R35-20260121","first-page":"1403","article-title":"[Advances in predictive biomarkers associated with immune checkpoint inhibitors for tumor therapy].","volume":"39","author":"Guo","year":"2023","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"R36-20260121","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy.","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:04:16Z","timestamp":1768993456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":36,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045876","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"2024-02-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}